CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-18 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −241 | $454.84 | $110K | 22,731 |
| 2025-08-18 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | −12 | $455.82 | $5K | 22,719 |
| 2025-08-18 | BONNEY MICHAEL W Director | Option exercise 10b5-1 | +11,250 | $70.20 | $790K | 28,054 |
| 2025-08-18 | BONNEY MICHAEL W Director | Sale 10b5-1 | −11,250 | $450.00 | $5.1M | 16,804 |
| 2025-08-18 | BONNEY MICHAEL W Director | Option exercise · Stock Option (right to buy) 10b5-1 | −11,250 | 0 | ||
| 2025-08-15 | Garg Pushkal EVP Chief R&D | Grant or award 10b5-1 | +2,851 | 23,072 | ||
| 2025-08-15 | Tanguler Tolga EVP, Chief Commercial Officer | Grant or award | +2,851 | 30,862 | ||
| 2025-08-15 | Poulton Jeffrey V. EVP, Chief Financial Officer | Grant or award | +4,644 | 52,395 | ||
| 2025-08-15 | Greenstreet Yvonne Chief Executive Officer | Grant or award | +14,252 | 63,200 | ||
| 2025-08-15 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Grant or award | +2,851 | 24,115 | ||
| 2025-08-14 | Ausiello Dennis A Director | Option exercise 10b5-1 | +9,000 | $72.01 | $648K | 9,911 |
| 2025-08-14 | Ausiello Dennis A Director | Option exercise 10b5-1 | +5,153 | $128.31 | $661K | 15,064 |
| 2025-08-14 | Ausiello Dennis A Director | Option exercise 10b5-1 | +4,581 | $148.77 | $682K | 19,645 |
| 2025-08-14 | Ausiello Dennis A Director | Option exercise 10b5-1 | +5,228 | $151.22 | $791K | 24,873 |
| 2025-08-14 | Ausiello Dennis A Director | Option exercise 10b5-1 | +4,032 | $171.95 | $693K | 28,905 |
| 2025-08-14 | Ausiello Dennis A Director | Option exercise 10b5-1 | +3,454 | $189.87 | $656K | 32,359 |
| 2025-08-14 | Ausiello Dennis A Director | Sale 10b5-1 | −1,985 | $430.81 | $855K | 30,374 |
| 2025-08-14 | Ausiello Dennis A Director | Sale 10b5-1 | −1,938 | $432.94 | $839K | 28,436 |
| 2025-08-14 | Ausiello Dennis A Director | Sale 10b5-1 | −2,098 | $434.50 | $912K | 26,338 |
| 2025-08-14 | Ausiello Dennis A Director | Sale 10b5-1 | −7,675 | $435.40 | $3.3M | 18,663 |
Page 26 of 41 · 816 trades